Feb 1, 2026
Does kisqali improve outcomes for ER positive HER negative metastatic breast cancer?
(ribociclib), a CDK4/6 inhibitor taken with endocrine therapy, improves key outcomes for people with ER‑positive, HER2‑negative metastatic breast cancer: randomized trials show meaningful increases in...